Re: Indevus's Testosterone Drug Found Effective in Phase III Hypogonadism Study

[Guest guest]

I have been looking into this a little bit... has anyone here tried

it ?

This is one report from a guy on the Anabolic Minds web site. I find

that a lot of body builders using steroids practically become

chemists and know more than many doctors. Unfortunately, this is not

a great review of the product. There were several other not so hot

reviews also. It seems to be the same testosterone roller coaster....

(dramatically peaking and declining levels of Testosterone ) that is

inherent with any HRT that I have ever heard about .

(here is the quote)

" I've been using it for over a year now. Nothing good to say about

it. But my doc insist staying on it. I take a shot every 4 weeks ! So

that's it for 4 shots per year. My levels before the last shot where

T=23 (10-38) Free T=506 (150-500) E2=0.15 (0-0.16). And he won't give

Adex or anything else to lower the E2. I think I'll try Zinc and see

what it does.

So stay away from Nebido if you can. "

samppa

>

>

> Indevus's Testosterone Drug Found Effective in Phase III

Hypogonadism Study

> Posted on: Wednesday, 21 May 2008, 12:00 CDT

> Indevus Pharmaceuticals has reported positive data from Phase III

study on

> Nebido, an investigational, long-acting intramuscular injection for

the

> treatment of hypogonadism.

> The study demonstrated that 94% of the men had their testosterone

levels

> restored and maintained to within normal levels; further, 92% of

these men

> expressed satisfaction with their Nebido treatment. Approximately

62% of men

> participating in the Phase III study had previously used other

testosterone

> treatments.

>

>

>

> In the study, pharmacokinetic objectives were achieved, with 94% of

patients

> reaching and maintaining normal serum testosterone levels.

Additionally,

> secondary endpoints of mood and sexual function also improved.

> This Phase III study was a multi-center, open-label, randomized US

trial to

> assess the pharmacokinetics, safety, and efficacy of Nebido in men

with

> primary or secondary hypogonadism. The trial enrolled a total of

130 hypogonadal

> men (serum testosterone below 300ng/dL, at least 18 years of age)

that met the

> study inclusion criteria. Patients received injections of 750mg of

Nebido at

> baseline, week four, and week 14 of the study, and were followed

for an

> additional 10 weeks. Of the 130 men who participated in the trial,

117 patients

> were eligible for pharmacokinetics evaluations.

> Source: Datamonitor

>

> Regards,

>

> Vergel

> Director

> Program for Wellness Restoration

> powerusa dot org

>

>

>

> **************Get trade secrets for amazing burgers. Watch " Cooking

with

> Tyler Florence " on AOL Food.

> (http://food.aol.com/tyler-florence?video=4 & ?

NCID=aolfod00030000000002)

>